Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Public ClinicalTrials.gov record NCT03602079. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
Study identification
- NCT ID
- NCT03602079
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Klus Pharma Inc.
- Industry
- Enrollment
- 49 participants
Conditions and interventions
Conditions
- Bile Duct Cancer
- Bladder Cancer
- Breast Neoplasm Malignant Primary
- Cervical Cancer
- Cholangiocarcinoma
- Colo-rectal Cancer
- HER-2 Gene Amplification
- HER2 Gene Mutation
- HER2 Positive Gastric Cancer
- HER2-positive Breast Cancer
- Head and Neck Cancer
- Head and Neck Carcinoma
- Larynx Cancer
- Lip Cancer Stage I
- Liver Cancer
- Lung Cancer
- Mouth Cancer
- Mucinous Adenocarcinoma Gastric
- Mucinous Breast Cancer Recurrent
- Mucoepidermoid Carcinoma
- Palate Cancer
- Pancreatic Cancer
- Primary Peritoneal Carcinoma
- Prostate Cancer
- Rare Diseases
- Rectal Cancer
- Rectal Cancer Stage I
- Rectal Cancer Stage II
- Rectal Cancer Stage III
- Recurrent Breast Cancer
- Recurrent Colon Cancer
- Recurrent Gastric Cancer
- Recurrent Ovarian Carcinoma
- Recurrent Prostate Cancer
- Recurrent Renal Cell Cancer
- Salivary Gland Cancer
- Salivary Gland Carcinoma
- Salivary Gland Neoplasms
- Salivary Gland Tumor
- Skin Cancer
- Solid Tumor
- Tongue Cancer
- Tonsil Cancer
- Urologic Cancer
Interventions
- A166 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 15, 2018
- Primary completion
- Jan 11, 2022
- Completion
- Jan 11, 2022
- Last update posted
- Aug 2, 2023
2018 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists & Research Institute | Sarasota | Florida | 34232 | — |
| Beth Israel Deaconess Medical Center Cancer Center | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Clinical Research Alliance, Inc. | Lake Success | New York | 11042 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Providence Cancer Institute | Portland | Oregon | 97213 | — |
| Mary Crowley Cancer Research Centers - Medical City | Dallas | Texas | 75230 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics, LLC (START) | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialist | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03602079, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2023 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03602079 live on ClinicalTrials.gov.